Physician

Kara L. Foster-Weiss, M,D

According to 2025 Medicare claims, Kara Foster-Weiss, M, D (NPI: 1669426961) practices family practice in the Richmond, VA market, with the plurality of this provider's patient population coming from Chesterfield, VA. This provider's primary affiliated billing organization is INFUSION SOLUTIONS LLC (NPI: 1831715929; TIN: 844626297) and primary practice location at 23226-3762. Foster-Weiss is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Foster-Weiss' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 963 traditional Medicare patients, billed 473,514 HCPCS/CPT codes, and received $5,446,346 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 3,444 prescription claims across 307 beneficiaries totaling $285,259 in drug costs, led by Eliquis (Apixaban). DME data shows 41 claims. Open Payments data shows 29 records totaling $22,139. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $198,573 to $5,446,346. In contrast, Part D prescription costs have moved from a higher plateau to a lower plateau, from $369,398 to $285,259. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $20,253 and ending at $11,134.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	917	4,539	$198,573
2016	842	4,678	$214,050
2017	868	5,242	$249,310
2018	755	3,837	$191,965
2019	438	2,040	$100,044
2020	400	2,579	$111,219
2021	464	2,614	$126,151
2022	322	41,351	$1,073,650
2023	614	180,690	$3,219,101
2024	963	473,514	$5,446,346

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	701	6,442	$369,398
2016	738	8,345	$537,815
2017	633	9,320	$641,219
2018	592	8,263	$655,831
2019	601	7,778	$715,629
2020	596	4,004	$376,933
2021	327	2,439	$218,393
2022	201	1,914	$158,292
2023	276	2,782	$272,461
2024	307	3,444	$285,259

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	39	255	$7,610
2016	51	285	$6,188
2017	104	423	$10,309
2018	89	495	$13,235
2019	57	323	$11,020
2020	37	220	$12,474
2021	N/R	136	$9,135
2022	N/R	31	$590
2023	N/R	46	$6,930
2024	N/R	41	$7,927

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	168	295	$60
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	183	449	$45
J0897	Injection, denosumab, 1 mg	225	17,880	$21
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	183	398	$12
96372	Injection of drug or substance under skin or into muscle	448	1,518	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	41	2,480	$46,858
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	29	1,590	$33,207
Trulicity	Dulaglutide	21	700	$23,612
Ozempic	Semaglutide	20	706	$21,810
Jardiance	Empagliflozin	13	810	$16,114

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	12	$6,967
E1392	Portable oxygen concentrator, rental	Y	N/R	18	$626
E0601	Continuous positive airway pressure (cpap) device	Y	N/R	11	$334

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	26	$548	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$21,591	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kara L. Foster-Weiss, M, D?

Tedicare shows public-source Medicare data for Kara L. Foster-Weiss, M, D (NPI 1669426961), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kara L. Foster-Weiss, M, D have ACO affiliation data?

Kara L. Foster-Weiss, M, D is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Kara L. Foster-Weiss, M, D?

Kara L. Foster-Weiss, M, D is linked to INFUSION SOLUTIONS LLC (billing NPI 1831715929) in the available physician profile data.

Does Kara L. Foster-Weiss, M, D have Open Payments data?

Kara L. Foster-Weiss, M, D has 29 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.